Vivid Dx Raises $15M Seed to Speed Sepsis Diagnosis
Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
Vivid Dx, an Oxford based precision diagnostics company, has raised $15 million in a seed round to speed up the diagnosis of dangerous infections. Oxford Science Enterprises and Cedars-Sinai Intellectual Property Co. jointly led the financing, which was announced on July 28, 2026.
Jameel Investment Management Company and other strategic investors also took part. Alongside the raise, Vivid Dx named scientist and diagnostics executive Keith O’Neill as its chief executive.
The company is working to improve treatment decisions for life threatening infections such as sepsis, while helping hospitals confront the spread of antimicrobial resistance. Its platform pairs AI and machine learning with advanced sample preparation and Raman spectroscopy to read biochemical signatures from individual pathogen cells, aiming for a rapid blood based test.
Vivid Dx plans to use the money to move its platform through clinical validation and testing with patient derived clinical samples.